182 related articles for article (PubMed ID: 26518305)
1. [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].
Eisenhardt A; Schneider T; Scheithe K; Colling C; Heidenreich A;
Urologe A; 2016 Feb; 55(2):176-83. PubMed ID: 26518305
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
Gilbert DC; Duong T; Kynaston HG; Alhasso AA; Cafferty FH; Rosen SD; Kanaga-Sundaram S; Dixit S; Laniado M; Madaan S; Collins G; Pope A; Welland A; Nankivell M; Wassersug R; Parmar MK; Langley RE; Abel PD
BJU Int; 2017 May; 119(5):667-675. PubMed ID: 27753182
[TBL] [Abstract][Full Text] [Related]
3. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
Merseburger AS; Hupe MC
Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
5. Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study.
Lebret T; Culine S; Davin JL; Hennequin C; Mignard JP; Moreau JL; Rossi D; Zerbib M; Mahmoudi A; Latorzeff I
Aging Male; 2014 Jun; 17(2):87-93. PubMed ID: 24576298
[TBL] [Abstract][Full Text] [Related]
6. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
8. Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study.
Prezioso D; Bartoletti R; Cecchi M; Cicalese V; Cunico SC; Damiano R; De Lisa A; Franzolin N; Frea B; Guazzoni G; Mearini E; Morgia G; Muzzonigro G; Oliva G; Orestano F; Pagliarulo A; Pappagallo GL; Parma P; Perachino M; Pompa P; Rocco F; Zattoni F;
Arch Ital Urol Androl; 2007 Sep; 79(3):99-103. PubMed ID: 18041358
[TBL] [Abstract][Full Text] [Related]
9. New-onset psychosis following androgen deprivation therapy for prostate cancer.
Bernad DM; Dal Pra A; Baule C; Frey BN; Faria S
Can J Urol; 2013 Aug; 20(4):6868-70. PubMed ID: 23930615
[TBL] [Abstract][Full Text] [Related]
10. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
[TBL] [Abstract][Full Text] [Related]
11. Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
Karunasinghe N; Zhu Y; Han DY; Lange K; Zhu S; Wang A; Ellett S; Masters J; Goudie M; Keogh J; Benjamin B; Holmes M; Ferguson LR
BMC Urol; 2016 Aug; 16(1):48. PubMed ID: 27485119
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
15. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
18. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
19. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
Park J; Shin DW; Yun SJ; Park SW; Jeon SS; Kwak C; Kwon TG; Kim HJ; Ahn H
Oncology; 2013; 85(5):299-305. PubMed ID: 24217330
[TBL] [Abstract][Full Text] [Related]
20. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
Beer TM; Schellhammer PF; Corman JM; Glodé LM; Hall SJ; Whitmore JB; Frohlich MW; Penson DF
Urology; 2013 Aug; 82(2):410-5. PubMed ID: 23896100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]